Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:…

By Yuichiro Ohe, Y. Ohashi, K. Kubota, T. Tamura, K. Nakagawa, S. Negoro, Y. Nishiwaki, N. Saijo, Y. Ariyoshi, M. Fukuoka. Annals of Oncology, 2006

645 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b5b43dd482b7fe03aad70eb1fd197d84c7f83daa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Yasushi Yatabe
2. T. Mitsudomi
3. Wei Wang

Citations in the corpus

• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, neutral): “Other individual trials found no difference in survival.(18,74,75)”
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (2008, background): “The median survival of metastatic NSCLC is 8 to 10 months when treated with the most active combination of conventional chemotherapeutic agents (1, 2).”